Clinical Trial Update: A Phase 2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Patients with DIPG [Phase 2]

View source ↗

Summary

Phase 2 study of SONALA-001 with Exablate 4000 Type 2.0 for diffuse intrinsic pontine glioma and diffuse midline glioma has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Intrinsic Pontine Glioma
• Diffuse Midline Glioma

Drugs mentioned

• Exablate 4000 Type 2.0
• SONALA-001

Snippet

Sponsor: SonALAsense, Inc. | Conditions: Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma | Phase 2 | Status: SUSPENDED